ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/PI3K
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/PI3K
4
trial(s) found.
NCT06757634
Advanced
Phase 3
Recruiting
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib With Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer (
CELC-G-302
)
CDK4/6 inhibitor
pan-PI3K/mTORC1/mTORC2 inhibitor
Breast cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4215 - Southport - ICON Cancer Care
SA
5000 - South Australia - GenesisCare St Andrews Hospital
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06208657
Paed
Phase 1 / Phase 2
Recruiting
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (
OPTIMISE
)
Irinotecan
Nivolumab
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Relatlimab
Temozolomide
alkylating agent
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
cancer therapy
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
topoisomerase inhibitor
+ PI3K alpha inhibitor
Cancer
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT03970447
Radonc
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
ATM inhibitor
AZD1390
Dianhydrogalactitol
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
Troriluzole
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,ATM-targeting
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
glutamate modulator
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
+ PI3K alpha inhibitor
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12624001340527
Advanced
Phase 1
Recruiting
A Phase 1b, Multi-centre, Open-label, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Activity of Combining Paxalisib with Olaparib or Pembrolizumab/Chemotherapy in Patients with Advanced Breast Cancer (
PaxPlus-ABC
)
PARP1/2 inhibitor
anti-PD-1 monoclonal antibody
dual PI3K/mTOR inhibitor
Breast cancer
NSW
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
ACT
2605 - Garran - The Canberra Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (4)
Recruitment Country and State
NSW (4)
QLD (3)
SA (3)
WA (2)
VIC (2)
TAS (1)
ACT (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 / Phase 3 (1)
Phase 3 (1)
Trial Type
Advanced (2)
Paed (1)
Paed (1)
Radonc (1)
Cancer Therapy Class
PI3K
100%
PI3Kalpha
100%
mTOR
100%
mTORC1
100%
mTORC2
100%
PI3K delta
75%
PD-1
50%
PD-1/PD-L1
50%
CDK4
25%
CDK6
25%
ER
25%
oestrogen axis
25%
LAG3
25%
ATM
25%
FGFR
25%
FGFR1
25%
FGFR1/2/3
25%
FGFR2
25%
FGFR3
25%
FGFR4
25%
KIT
25%
PDGFR
25%
RET
25%
VEGFR
25%
PARP
25%
Facility
2076 - Wahroonga - Sydney Adventist Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
4215 - Southport - ICON Cancer Care (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2031 - Randwick - Sydney Children's Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
3168 - Clayton - Monash Children's Hospital (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (1)
6009 - Perth - Perth Children's Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
2605 - Garran - The Canberra Hospital (1)
Cancer Type
Cancer
Solid tumour
Breast cancer
Central nervous system cancer
Neurological cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy